Since we had found effects of the CaMKII inhibitor KN-93 on HIF-1α expression we decided to include the novel CaMKII inhibitor SMP-114 (in phase 2 clinical trial for treatment of RA). This evidence concerns the gene CAMK2G and rheumatoid arthritis.